TipRanks
Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M
📈
AI Sentiment
Highly Positive
8/10
Fortress Biotech Inc. News
Latest updates and market news for FBIOP
5 news
Feb 20 - Feb 26, 2026
Page 1
GlobeNewswire
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Fortress Biotech Subsidiary Agrees to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
➖
AI Sentiment
Neutral
5/10
GlobeNewswire
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
📈
AI Sentiment
Highly Positive
9/10
GlobeNewswire
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
📈
AI Sentiment
Highly Positive
8/10
Share this news page